Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Q4 2024 value amounting to $4.5 million.

  • Ironwood Pharmaceuticals' Non-cash Items rose 5548.85% to $4.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 million, marking a year-over-year increase of 5548.85%. This contributed to the annual value of $4.5 million for FY2024, which is 2220.62% down from last year.
  • As of Q4 2024, Ironwood Pharmaceuticals' Non-cash Items stood at $4.5 million, which was up 5548.85% from $2.9 million recorded in Q4 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-cash Items peaked at $5.8 million during Q4 2022, and registered a low of $2.9 million during Q4 2023.
  • For the 5-year period, Ironwood Pharmaceuticals' Non-cash Items averaged around $4.7 million, with its median value being $4.5 million (2024).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Non-cash Items plummeted by 7774.91% in 2020 and then soared by 5548.85% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Non-cash Items (Quarter) stood at $5.6 million in 2020, then decreased by 19.33% to $4.5 million in 2021, then rose by 27.78% to $5.8 million in 2022, then crashed by 49.53% to $2.9 million in 2023, then skyrocketed by 55.49% to $4.5 million in 2024.
  • Its last three reported values are $4.5 million in Q4 2024, $2.9 million for Q4 2023, and $5.8 million during Q4 2022.